Evogene Ltd. (NASDAQ:EVGN) does about 215.31K shares in volume on a normal day but saw 3498874 shares change hands in Tuesday trading. The company now has a market cap of 70.57M USD. Its current market price is $2.74, marking an increase of 32.37% compared to the previous close of $2.07. The 52 week high reached by this stock is $2.15 whilst the lowest price level in 52 weeks is $0.75. The script in recent trading has seen the stock touch a high of $2.80 and a low of $2.0842.

Evogene Ltd. (EVGN) has a 20-day trading average at $1.50 and the current price is 27.44% off the 52-week high compared with 265.33% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.24 and its 200-day simple moving average is $1.27. If we look at the stock’s price movements over the week, volatility stands at 17.43%, which decreases to 11.23% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 92.86 to suggest the stock is overbought.

1 analysts observing the Evogene Ltd. (EVGN) stock have set the 12-month price targets for the company’s shares at between $8.00 and $8.00. The median price target is 65.75% away from the current levels at $8.00.

FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 0 analysts have rated it as a buy and 1 have advised that investors hold their positions. The consensus recommendation rating is Hold and Wall Street’s advice is for investors to Hold the stock.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on December 16, 2013 when Oppenheimer initiated the stock to “Outperform” and issued a price target of $26.

The current price level is 93.43%, 127.69%, and 117.46% away from its SMA20, SMA50, and SMA200 respectively, with the EVGN price moving below the 50-day SMA on September 01. Evogene Ltd. (EVGN) stock is up 65.06% over the week and 146.85% over the past month. Its price is 80.26% year-to-date and 77.92% over the past year.

The stock last released its quarterly earnings report for quarter ended 12/30/2017, with the company’s earnings per share (EPS) of -$0.24 below consensus estimates by -$0.03. The company’s next earnings report is expected on 11/18/2020. Expected sales for next quarter are $1.9 million, which analysts say will come at $9.2 million for the current fiscal year and next year at $80 million. In addition, estimates put the company’s current quarterly revenue at an average of $1.9 million.

Its 12-month price target is $8.00. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $8.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $8.00.

Outstanding shares total 25.75M with insiders holding 12.33% of the shares and institutional holders owning 28.37% of the company’s common stock. Price to book ratio is 1.77 and price to sales ratio is 120.42.

According to a U.S. Securities and Exchange Commission filing, Ivy Funds – Science & Technology has reduced its position in Evogene Ltd. (EVGN) to 2,620,002 shares, mirroring a recent drop by 0.00%. Ivy Funds – Science & Technology dumped 0.0 shares of Evogene Ltd. common stock bringing its total worth to about $2.7 million at the end of recent close, SEC documents show. Ivy Funds – Science & Technology isn’t the only investment manager who changed stakes and is followed by ARK Genomic Revolution ETF, which added 1564.0 shares to end up with 479,003 shares worth $0.49 million. More TA Mid Cap (4B) cut their holdings by 0.00% in the company over the course of the most recent quarter. It now holds a 1.21% position in Evogene Ltd. thanks to 0.31 million shares amounting to $0.32 million.